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The mitochondrial DNA mutation m.1555A>G predisposes to hearing loss following aminoglycoside antibiotic
exposure in an idiosyncratic dose-independent manner. However, it may also cause maternally inherited hear-
ing loss in the absence of aminoglycoside exposure or any other clinical features (non-syndromic hearing loss).
Although m.1555A>G was identified as a cause of deafness more than twenty years ago, the pathogenic mech-
anism of this mutation of ribosomal RNA remains controversial. Different mechanistic concepts have been pro-
posed. Most recently, evidence from cell lines and animal models suggested that patients with m.1555A>G may
have more 12S rRNA N6, N6–dimethyladenosine (m62A) methylation than controls, so-called ‘hypermethyla-
tion’. This has been implicated as a pathogenic mechanism of mitochondrial dysfunction but has yet to be vali-
dated in patients. 12S m62A rRNA methylation, by the mitochondrial transcription factor 1 (TFB1M) enzyme,
occurs at two successive nucleotides (m.1584A and m.1583A) in close proximity to m.1555A>G. We examined
m62A methylation in 14 patients with m.1555A>G, and controls, and found all detectable 12S rRNA transcripts
to be methylated in both groups. Moreover, different RNA samples derived from the same patient (lymphocyte,
fibroblast and lymphoblast) revealed that only transformed cells contained some unmethylated 12S rRNA tran-
scripts, with all detectable 12S rRNA transcripts derived from primary samples m62A-methylated. Our data indi-
cate that TFB1M 12S m62A rRNA hypermethylation is unlikely to be a pathogenic mechanism and may be an
artefact of previous experimental models studied. We propose that RNA methylation studies in experimental
models should be validated in primary clinical samples to ensure that they are applicable to the human situation.
INTRODUCTION
One in 520 people carries a maternally inherited mitochondrial
DNA (mtDNA) mutation, m.1555A.G, which predisposes to
irreversible hearing loss following aminoglycoside antibiotic
exposure (1,2). In a high proportion of cases, m.1555A.G
leads to profound hearing loss following standard doses of ami-
noglycoside antibiotics (3). However, some family studies have
reported maternally inherited deafness in the absence of amino-
glycoside exposure. Because there are no additional clinical fea-
tures, and to distinguish it from antibiotic-associated deafness, it
has been termed ‘non-syndromic’ deafness (4,5). In these fam-
ilies, increased penetrance of m.1555A.G is attributed to
nuclear modifier genes (5–8).
m.1555A.G is a homoplasmic mtDNA mutation, located in
theMT-RNR1 gene, which encodes the mitochondrial ribosomal
12S RNA (12S rRNA). The m.1555A.G 12S rRNA mutation is
located in the ribosomal aminoacyl-tRNA-acceptor site (A-site),
where the correct tRNA is matched to the correct mRNA codon
during protein synthesis (Fig. 1A). The mitochondrial ribosome
translates 11 mtDNA-encoded mRNAs into indispensable poly-
peptide subunits of the mitochondrial oxidative phosphorylation
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system (OXPHOS). OXPHOS is an essential biochemical
energy production process involved in the synthesis of .90%
of cellular ATP. The pathogenic mechanism of m.1555A.G
is unclear, and two discordant mechanisms of mitochondrial
dysfunction have been postulated (9–14). Broadly, these two
mechanisms can be classified as mRNA misreading and 12S
rRNA methylation (Fig. 1B and C).
The first, long-standing hypothesis centres on the ability of
the mitochondrial ribosome to discriminate between the
correct, cognate tRNA and the incorrect, near-cognate tRNA
during protein synthesis (Fig. 1B) (9,10). This hypothesis
suggests that mitochondrial dysfunction in the presence of
m.1555A.G occurs when the accuracy of ribosomal mRNA
reading of 11 OXPHOS mRNAs has fallen below a minimum
threshold level necessary for the basic metabolic requirements
of cochlear cells (11). Early reports proposed this mechanism
because it mirrors the orthologous mechanism of aminogly-
coside action on gram-negative bacteria (4,9,10). Functional
analysis of artificial hybrid ribosomes engineered to have
m.1555A.G has since shown that m.1555A.G leads to a
7-fold increase in mRNA misreading and that mRNA misread-
ing is further elevated in the presence of aminoglycoside antibio-
tics (11,15).
In 2003, a second alternative hypothesis was proposed.
Seidel-Rogul et al. hypothesized that the nuclear-encoded mito-
chondrial transcription factor 1 (TFB1M) enzyme may play a
role in m.1555A.G hearing loss (Fig. 1C) (12). TFB1M
belongs to a highly conserved family of RNA methyltransferases
responsible for the N6, N6–dimethyladenosine (m62A) methy-
lation of two successive adenosine nucleotides near the 3′ end
of small rRNA subunits in almost all species (16–18). In the
Homo sapiens mitochondrial ribosome, the 12S rRNA is m62-
A-methylated at positions m.1584A and m.1583A (Fig. 2A
and B) (16,18). The highly conserved nature of the m62A modi-
fication enzyme and the presence of two successive m62-
A-methylated adenosines on almost all known small ribosomal
subunits suggest a key cellular function for this modification
(16–19). Studies indicate that m62A methylation may act as a
checkpoint during ribosome biogenesis, preventing immature
small rRNAs from prematurely entering the translational cycle
and causing ribosomal dysfunction (19). First reported in
1958, m62A methylation is also known to modulate bacterial sus-
ceptibility to the aminoglycoside antibiotic kasugamycin, and
studies have shown that, in a TFB1M knockout mouse, mito-
chondrial translation is severely impaired in the absence of
m62A rRNA methylation (12,19,20).
Figure 1. (A) m.1555A.G is located in the A-site, where the correct tRNA (cognate tRNA) anticodon and mRNA codon are matched during protein synthesis. (B)
mRNA misreading has been postulated as a pathogenic mechanism for m.1555A.G mitochondrial dysfunction following aminoglycoside exposure, as the fidelity of
translation decreases below a threshold level required for cochlear function. This mechanism is also consistent with the nuclear genes, MTO1, GTPBP and TRMU,
reported to modify the penetrance of m.1555A.G hearing loss. (C) Evidence from transgenic cancerous cells and a transgenic mouse model indicates that patients
with m.1555A.G may have more 12S m62A rRNA methylation than controls, so-called hypermethylation. m
6
2A methylation occurs at two successive adenosines
(m.1584A and m.1583A) on the 12S rRNA in close proximity to m.1555A.G.
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Seidel-Rogul et al. hypothesized that m62A rRNA ‘hyper-
methylation’ on the mitochondrial 12S rRNA may influence
the pathogenicity of m.1555A.G hearing loss (12–14). The
term hypermethylation refers to an increase in the number of
methylated residues in RNA or DNA compared with controls.
The 12S rRNA hypermethylation hypothesis stems from the
proximity of m.1583A and m.1584A to m.1555A.G (Fig. 2A
and B) and the ability of m62A methylation to modulate amino-
glycoside susceptibility in bacteria.
Here, to establish the clinical relevance of 12S rRNA methy-
lation in m.1555A.G hearing loss, 12S m62A rRNA methyla-
tion was examined in 35 RNA samples - including primary
lymphocyte RNA from 14 patients with m.1555A.G and 12 un-
related controls. A number of non-primary RNA samples from
143B.TK- and HeLa cell lines were also examined as controls.
RESULTS
To examine the potential role of TFB1M in m.1555A.G
hearing loss, 12S m62A rRNA methylation was examined
using a fluorescent primer extension assay (Fig. 3) (21).
Primer extension analysis of synthetic RNA templates
Four synthetic RNA oligonucleotides, designed to replicate the se-
quence of the mitochondrial 12S rRNA, were used as assaycontrols
(Fig. 3). Analysis of synthetic unmethylated and methylated RNA
oligonucleotides showed: (A) termination of primer extension
occurs after 48 bp when the RNA oligonucleotide is unmethylated,
owing to the presence of 2′,3′-Dideoxyguanosine-5′-Triphosphate
(ddGTP) in the reaction and a cytosine nucleotide in the cor-
responding position in the template RNA; (B) an RNA
oligonucleotide m62A-methylated at the equivalent of
m.1584A terminates at 42 bp, i.e. the presence of m62A methy-
lation does not allow further extension (21); (C) m62A methyla-
tion at the equivalent of m.1583A leads to termination at 43 bp;
(D) primer extension on a template m62A-methylated at the
equivalent of m.1584A and m.1583A showed that it is not pos-
sible to detect m.1583A m62A methylation in this situation
(Fig. 3). Figure 3 (E) shows that all three templates present in
the reaction together can be detected simultaneously in our
primer extension assay.
Primer extension analysis of native RNA samples
Consistent with earlier findings by others, we found HeLa 12S
rRNA and a 143B.TK2 cell line to be partially methylated
(Fig. 4A and Supplementary Material, Fig. S2A) (13). Mean per-
centage (+SD) of methylated HeLa 12S rRNA was 80.7+
0.3% (n ¼ 3), calculated using area under the curve. Analysis
of a control r0 206 cell line, lacking mtDNA, showed no
primer extension, confirming primer specificity to the mitochon-
drial transcriptome (Fig. 4B and Supplementary Material,
Fig. S2).
Primer extension analysis of primary lymphocyte RNA from
14 patients with m.1555A.G (pedigrees shown in Fig. 5) and 12
controls showed that all detectable 12S rRNA appeared fully
m62A-methylated at m.1584A in both groups (Fig. 4 and Supple-
mentary Material, Fig. S1). We found that the absolute quantity
of 12S rRNA transcript in 10 mg of RNA varied between indivi-
duals, but in all cases, no unmethylated transcript could be
detected using our fluorescent assay (Supplementary Material,
Fig. S1). Individuals with mild hearing loss and severe hearing
loss all showed full 12S m62A rRNA methylation at position
m.1584A with no detectable unmethylated transcripts.
Figure 2.Evidence from experimental models proposes that m.1555A.G results in m.1584A and m.1583A m62A hypermethylation - the proximity of these residues
to m.1555A.G is shown in (A) the secondary structure of the 3′ end of the H. sapiens 12S rRNA and (B) the tertiary structure of Thermo thermophilus A-site (PDB:
3I8H).
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Analysis of fibroblast, lymphocyte and lymphoblastoid cell-
derived RNA from the same patient with m.1555A.G showed
that 12S rRNA isolated from primary cells was methylated
with no unmethylated species detected but, in marked contrast,
some 12S rRNA isolated from the transformed lymphoblastoid
cell line was unmethylated (Fig. 6). Unmethylated 12S rRNA
was also observed in three further lymphoblastoid cell lines
(Table 1). Thus, 12S m62A rRNA methylation status appears
Figure 3. Primer extension of control synthetic RNA oligonucleotides, replicates of the reported native 12S rRNA methylated and unmethylated transcripts demon-
strates: (A) termination of primer extension occurs after 48 bp when the RNA oligonucleotide is unmethylated, owing to the presence of ddGTP in the reaction and a
cytosine nucleotide in the corresponding position in the template RNA; (B) an RNA oligonucleotide m62A-methylated at the equivalent of m.1584A terminates at
42 bp, as the presence of m62A methylation does not allow further extension; (C) m
6
2A methylation at the equivalent of m.1583A leads to termination at 43 bp;
(D) primer extension on a template m62A-methylated at the equivalent of m.1584A and m.1583A showed that it is not possible to detect m.1583A m
6
2A methylation
in this situation. (E) All three templates present in the reaction together can be detected simultaneously in our primer extension assay. The primer is 38 bp in length.
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to correlate with cell status (primary or not) but not the
m.1555A.G genotype (Table 1).
DISCUSSION
In 2003, Seidel-Rogul et al. hypothesized that 12S m62A rRNA
methylation may be important for mitochondrial dysfunction
in the presence of m.1555A.G (12). The hypothesis stems
from the proximity of m62A-methylated nucleotides to
m.1555A.G and the ability of m62A methylation to modulate
aminoglycoside susceptibility in bacteria in vitro (12). The
first functional evidence suggesting TFB1M as a modulator of
m.1555A.G hearing loss came from studies of transmitochon-
drial cybrids (13). These are transgenic cell lines containing the
mitochondria from an immortal lymphoblastoid m.1555A.G
cell line (itself derived from transforming peripheral blood
lymphocytes) and the nucleus from a highly proliferative
143B.TK2 osteosarcoma cancer cell line (13,22). Studies of
this cybrid demonstrated that the 12S rRNA had relatively
increased m62A methylation at m.1584A and at m.1583A in a
patient cell line (a 1 : 1 ratio of methylated : unmethylated
transcripts) compared with a control cell line (a 1 : 2 ratio of
methylated : unmethylated transcripts) (13). Mouse models of
m.1555A.G do not currently exist owing to technical limita-
tions in mutagenesis of mtDNA, but a transgenic mouse model
overexpressing TFB1M was reported to have hearing loss com-
pared with its wild-type counterpart (23,24).
Genetic evidence also supported the involvement of TFB1M
in m.1555A.G hearing loss. Non-parametric analysis of
families with m.1555A.G and non-syndromic hearing loss
showed linkage to markers within the TFB1M gene on chro-
mosome 6 (25). Bykhovskaya et al. speculated that the
m.1555A.G mutation may be more penetrant in the presence
of 12S m62A rRNA hypomethylation, and protective alleles in
TFB1M may lead to 12S m62A rRNA hypermethylation (25).
However, in the present study, we have shown that all 12S
rRNA transcripts appear to be m62A-methylated in primary
RNA in both patients and controls. This contrasts with previous
observations in m.1555A.G 143B.TK2 osteosarcoma cell
cybrids in which there is a 1 : 2 ratio of methylated : unmethy-
lated transcripts in control and a 1 : 1 ratio of methylated :
unmethylated transcripts in m.1555A.G RNA (13). Our evi-
dence from primary and non-primary cells suggests that in
Figure 4.Primer extension of native RNA reveals: (A) HeLa 12S rRNA is partially methylated at m.1584A and unmethylated; (B) Controlr8 206 RNA, containing no
mtDNA, shows no primer extension; (C) all detectable m.1555A.G lymphocyte 12S rRNA appears to be fully methylated at m.1584A; (D) all detectable control
lymphocyte 12S rRNA appears to be fully methylated at m.1584A.
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H. sapiens large quantities of unmethylated 12S rRNA are un-
likely to exist in the normal situation. The unmethylated 12S
rRNA found in non-primary cells may be an artefact of tissue
culture, passage number or the aberrant cancerous nuclear
genome - known to have altered DNA methylation (26,27).
DNA methylation has been shown to differ between blood lym-
phocytes and lymphoblastoid cells lines, and methylation pat-
terns seen in cell lines may not always be representative of the
methylation present in the patient lymphocytes (27). There is
considerable variability in relation to levels of m62A methylation
in the literature; however, our evidence in primary H. sapiens
cellular RNA is consistent with independent lines of evidence
in bacteria and higher plants in which all detectable 12S rRNA
appears to be fully methylated (23,28).
Previous work had suggested that m.1583A 12S m62A rRNA
methylation is detectable in 143B.TK2 cells. As we have also
shown that it is not possible to detect m.1583A methylation if
m.1584A is m62A-methylated, our data indicate that previous
observations may be an artefact of the radioactive primer exten-
sion method used in previous work (13). Our data also strongly
suggest that m.1584A is m62A methylated by TFB1M before
m.1583A inH. sapiens, which is in agreement with the structural
evidence suggesting that the bacterial homologue of TFB1M,
KsgA, methylates the bacterial equivalent of m.1584A prior to
m.1583A (29).
Clinically, the concept of mRNA misreading is consistent
with the unique sensitivity of patients with m.1555A.G to ami-
noglycoside antibiotic-associated hearing loss, which is
believed to occur when the fidelity of translation of proteins
required for OXPHOS is insufficient to sustain the basic
energy requirements of cochlear cells. Misreading increases in
the presence of aminoglycosides (11). It is also consistent with
three of the four candidate genes reported to modify the pene-
trance of m.1555A.G, leading to hearing loss in the absence
of aminoglycoside exposure. Candidate nuclear modifiers of
m.1555A.G include: mitochondrial transcription optimiza-
tion 1 (MTO1); GTP binding protein 3 (GTPBP3); and 5-
methylaminomethyl-2-thiouridylate methyltransferase (TRMU).
MTO1, GTPBP3 and TRMU are tRNA modification enzymes,
involved in the metabolism of mitochondrial tRNAs (mt-
tRNAs), particularly the post-transcriptional modification at
position 34 on five specific mt-tRNAs (Fig. 1B) (6–8). Modi-
fication at mt-tRNA position 34 modulates the ability of the
mitochondrial ribosome to discriminate mRNA codonswith a dis-
criminator, wobble base (e.g. mt-tRNAs for leucine and phenyl-
alanine) (Fig. 1B). Variants in these candidate modifier genes
are believed to increase levels of mRNA misreading in patients
with non-syndromic m.1555A.G hearing loss (6–8).
In light of our evidence, the concept of mRNA misreading
demonstrated by Hobbie et al. stands as the remaining
Figure5.Primary lymphocyte 12S m62A rRNA methylation was examined in 14
patients with m.1555A.G from three unrelated families. ∗ Indicates aminogly-
coside exposure. + Indicates individuals sampled.
Figure 6. Primer extension analysis of 12S m62A rRNA methylation in three different samples from the same patient (A) primary lymphocyte, (B) primary fibroblast
and (C) transformed lymphoblastoid RNA. All detectable lymphocyte and fibroblast 12S rRNA appears to be fully methylated, but some 12S rRNA is unmethylated in
the lymphoblastoid RNA.
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mechanistic hypothesis for both non-syndromic hearing loss and
aminoglycoside ototoxicity in patients with m.1555A.G (11).
Therefore, strategies to reduce the binding affinity of aminogly-
coside antibiotics to H. sapiens mitochondrial ribosomes, to in-
crease the threshold accuracy level of m.1555A.G ribosomes
and/or to mitigate the mitochondrial dysfunction triggered by
aminoglycosides represent the greatest opportunity to shape
the development of future patient interventions (30–32).
Twenty years from the discovery of m.1555A.G, the
mechanism of action of this mutation and particularly factors de-
termining its penetrance will be of interest to the wider mito-
chondrial disease community. Thus, continued study of factors
influencing the penetrance of homoplasmic mtDNA mutations
such as m.1555A.G, without the confounding contribution of
heteroplasmy, may unlock our understanding of nuclear modi-
fier genes governing the tissue specificity and clinical variability
associated with many severe mitochondrial diseases (33).
Given the large difference that appears to exist between the
cybrid m.1555A.G RNA and primary patient m.1555A.G
RNA, we propose that RNA methylation studies in transformed
cells should be validated in primary clinical samples to ensure
that they are applicable to the human situation. RNA epigenetics
is a growing area of disease biology, and validation in primary
RNA samples is essential to maximise clinical relevance of
RNA epigenetics (34,35).
CLINICAL INFORMATION
Family 1 consists of two siblings and their parents (Fig. 5).
Neither child has been exposed to aminoglycosides; both were
born without perinatal problems, and neither had been in hospital
prior to cochlear implantation. In the first child, parents became
concerned about hearing at 1 year of age and severe sensori-
neural hearing loss (SNHL) was diagnosed around 3 years. By
9 years of age, his hearing loss had progressed to profound and
he underwent bilateral cochlear implantation aged 18.5 years,
following implantation of his sister (see below). There was no
obvious family history of hearing loss, but audiometry revealed
that both mother and maternal grandmother had mild high-
frequency SNHL.
Case III-2 is the younger sister of case III-1. She was born 3.5
years later following a normal pregnancy and delivery. Her
hearing was tested by auditory brainstem responses (ABR) and
otoacoustic emissions (OAE) at 6 weeks: ABR showed normal
click-evoked responses, and OAE were clearly demonstrable
on the left, less so on the right. At age 2 years, she was re-tested
and found to have a moderate-to-severe hearing loss. Hearing
loss was profound in the left ear by 3.5 years and in the right
ear by 5.5 years. She received a unilateral cochlear implant
aged 10 years with a second implant at 15 years. Clinical exam-
ination of both siblings was normal. She was diagnosed with
m.1555A.G aged 4 years, at the same time as her brother,
who was then aged 7 years.
In Family 2, case II-1 is the first child of unrelated Sudanese
parents and was born in the UK at 42 weeks of gestation follow-
ing a normal pregnancy and uneventful vaginal delivery. She
failed newborn hearing screening and was diagnosed with bilat-
eral moderate to severe SNHL by ABR aged 2 months. At 10
months, she had a pyrexial illness with lymphadenopathy and
was subsequently diagnosed with autoimmune neutropaenia.
She received six doses of co-amoxiclav intravenously, but no
aminoglycosides. She was diagnosed with m.1555A.G aged
3 years 8 months and underwent bilateral cochlear implantation
at this age because her hearing loss was profound. She has never
received aminoglycosides.
Case II-2 is her younger brother. Delivery was normal but, in
view of prolonged rupture of membranes (PROM), he was
given five doses of benzyl penicillin (147 mg) and two doses
of gentamicin (14.7 mg), the first at birth and the second 24 h
later according to standard protocols for PROM. He failed
newborn hearing screening aged 3 weeks, and hearing loss
was confirmed at 4 weeks. ABR testing at 3 months showed
bilateral profound hearing loss. He was tested and found to
have m.1555A.G at 13 months and received bilateral cochlear
implants aged 2 years but has had no other hospital admissions.
Clinical examination was normal in both siblings. Both parents
have normal hearing up to and including 8 kHz, but mother has
a maternal history of hearing loss starting in the fourth decade
(her maternal grandmother, one maternal aunt and two mater-
nal uncles).
Family 3 consists of twins, their older brother and their mother
who are Ghanaian in origin. The first child was born following a
normal pregnancy and delivery. In the twin pregnancy, there
were no complications before 36 weeks when there was
PROM. Both twins were delivered by Caesarian section
because of a maternal history of uterine fibroids requiring myo-
mectomy. Twin 1 was a female weighing 3.01 kg, and Twin 2
Table 1. Summary of the primer extension results of the 35 native RNA samples analysed in this study
Species Cell type Cell status Unmethylated 12S rRNA detected? m.1555A.G No. of samples Replicates
H. sapiens Lymphocyte Primary 2 + 14 3a
H. sapiens Fibroblast Primary 2 + 1 3
H. sapiens Lymphocyte Primary 2 2 12 3
H. sapiens Fibroblast Primary 2 2 1 3
H. sapiens Lymphoblastoid Non-primary + + 2 2
H. sapiens Lymphoblastoid Non-primary + 2 2 2
H. sapiens HeLa Non-primary + 2 1 3
H. sapiens 143B.TK- Non-primary + 2 1 3
H. sapiens 143B.TK-r0 Non-primary No primer extension 2 1 3
Total number of samples analysed 35
aFour patients were analysed in duplicate, as indicated in Supplementary Material, Figure S1.
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(the proband), a male weighing 2.89 kg. In view of PROM, both
twins were given Benzyl Penicillin and Gentamicin according to
protocol for PROM. They received two doses, levels were
normal and medication was stopped on Day 3. Both twins
passed the newborn hearing screen.
Twin 2 had normal speech development, but he was found to
have a hearing loss on school entry at 4 years. Current testing at
age 8 years shows him to have a moderate asymmetrical
hearing loss, worse in the high frequencies [maximum 60 dec-
ibels hearing level (dBHL) at 2 kHz in the right ear and
50 dbHL at 4 kHz in the left ear]. Following discovery of
hearing loss in Twin 2, Twin 1 who had expressive language
delay at age 7 years was tested; she has a mild–moderate
high-frequency hearing loss, milder than her brother. The
20-year-old brother of the proband has normal hearing.
The mother has a mild bilateral hearing loss, which reaches
moderate in the high frequencies. In the family history, there
is also reported childhood-onset hearing loss in the maternal
uncle and aunt (mother’s maternal half-siblings), and
adult-onset hearing loss in the maternal grandmother and
maternal great uncle.
METHODS
Synthetic RNA oligonucleotides
Methylation was detected using a primer extension protocol
(Fig. 3). Unmethylated and methylated model RNA oligonu-
cleotides were synthesized (Thermo Scientific) to replicate
each of the reported native RNA conditions (12,13). One
microliter of 10–20 nM RNA oligonucleotide was incubated
with 1 ml of 50–100 nM 5′-Ned-labelled primer and 20 units
of RNAse Inhibitor (NEB) at 558C for 20 min. Twenty units
of Avian Myeloblastosis Virus (AMV) Reverse Transcriptase
(NEB), ×10 reaction buffer, 20 units of RNase Inhibitor
(NEB) and 1 ml 500 nM dNTP stock (containing ddGTP in
place of dGTP) were added, and the reaction mixture was incu-
bated overnight at 428C in a final volume of 10 ml. One micro-
liter was mixed with 8.95 ml Hi-Di Formamide (Applied
Biosystems) and 0.05 ml GeneScan Rox size standard
(Applied Biosystems) and run on an ABI3130 Genetic Analys-
er (Applied Biosystems). GeneMarker software (SoftGenetics)
was used for fragment analysis. Reactions were performed in
triplicate.
The 38-bp, HPLC-purified, 5′ Ned-labelled DNA primer used
was 5′ ACATCATCATCATCATCATCATTCGGTTCGTC
CAAGTG 3′. A 25-bp tail sequence was added to make the
primer 38 bp in length, the minimum reliable length that is
compatible with fragment separation on the ABI3130 sequencer.
The synthetic, HPLC-purified, model RNA oligonucleotides
used (Dharmacon) were as follows: 5′ AAGUGUACUGGAAA
GUGCACUUGGACGAAC 3′ for the unmethylated RNA tem-
plate, 5′ CUGGAdmAAGUGCACUUGGACGAACC 3′ for the
template methylated at the equivalent of m.1584A, 5′ CUGGd
mAAAGUGCACUUGGACGAACC 3′ for the template methy-
latedat theequivalentof m.1583Aand5′ CUGGdmAdmAAGUG
CACUUGGACGAACC 3′ for the template methylated at the
equivalent of m.1584A and m.1583A. dm in the oligonucleotide
sequence represents m62A (N6, N6-dimethyladenosine).
Patient tissues and cell lines
Ethical approval for this work was obtained from the National
Research Ethics Service Committee London Bloomsbury, UK.
Total RNA was isolated from 12 control and 14 m.1555A.G
patient lymphocyte samples using a Tempus RNA Isolation
Kit (Applied Biosystems) and concentrated using 3 K centri-
fugal units (Millipore). m.1555A.G was detected using restric-
tion digestion and Sanger sequencing. First, a 339-bp fragment
was amplified by PCR (forward primer 5′ GCTCAGCCTATA
TACCGCCATCTTCAGCAA 3′ and reverse primer 5′ TTT
CCAGTACACTTACCATGTTACGACTGG 3′) (3). Samples
were digested using HaeIII restriction digestion according to
the manufacturer’s instructions and fragments resolved on a
2% w/v TBE agarose gel (3). Digestion of the wild-type allele
results in two fragments 216 bp and 123 bp in length. The
m.1555A.G mutation creates a novel HaeIII restriction site,
resulting in three fragments 216, 93 and 30 bp in length (3).
All samples showing a restriction site gain were sequenced
by Sanger sequencing to confirm the presence of the
m.1555A.G mutation.
Control and m.1555A.G primary fibroblast cells were cul-
tured in high-glucose Dulbecco’s Modified Eagle Medium
(DMEM) (Gibco) supplemented with 10% foetal bovine serum
(FBS) (Sigma) and 50 mg/ml uridine (Sigma). Fibroblasts
were isolated using an established isolation protocol in the
absence of aminoglycoside antibiotics. Control and
m.1555A.G lymphoblastoid cells were cultured in high-
glucose RPMI (Life Technologies) supplemented with 10%
FBS (Sigma). The cancerous bone 143B.TK- and 143B.TK-r0
206 cell lines were a kind gift from Dr J.-W. Taanman. The
HeLa and 143B.TK2 cell lines were cultured in high-glucose
DMEM supplemented with 10% FBS. The 143B.TK2 r0 cell
line was supplemented with 50 mg/ml uridine. Cells were free
of mycoplasma infection (Promocell).
Primer extension—native RNA
Total RNA (10 mg) was incubated with 4 nM 5′-Ned-labelled
primer at 558C for 20 min. Twenty units of AMV Reverse Tran-
scriptase (NEB), ×10 reaction buffer, 20 units of RNase Inhibi-
tor (NEB) and 1 ml of 500 nM dNTP stock (containing ddGTP in
place of dGTP) were added. The reaction was incubated over-
night at 428C, desalted using 3K-centrifugal filters (Millipore),
vacuum desiccated and re-suspended in 8.95 ml HiDi Forma-
mide (Applied Biosystems), 1 ml dH2O and 0.05 ml GeneScan
Rox size standard (Applied Biosystems). Reactions were run
and analysed as described previously. Samples were analysed
in triplicate.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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